{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:00:17Z","timestamp":1757455217998,"version":"3.41.0"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adult atopic dermatitis (AD), especially adult\u2010onset type appears to have different clinical manifestations. Dupilumab is an IL\u20104 receptor antagonist used in patients with moderate and severe atopic dermatitis, aged 12\u00a0years and older and it works by inhibiting the IL\u20104 and IL\u201013\u00a0signaling pathway. The purpose of our study is to retrospectively investigate the side effect profile and drug efficacy of thirteen adult patients who received dupilumab treatment and to evaluate the drug use status and the results during the COVID\u201019 pandemicour stuAdult atopic dermatitis (AD), especially adult\u2010onset type appears to have different clinical manifestations. Dupilumab is an IL\u20104 receptor antagonist used in patients with moderate and severe atopic dermatitis, aged 12\u00a0years and older and it works by inhibiting the IL\u20104 and IL\u201013\u00a0signaling pathway. The purpose of our study is to retrospectively investigate the side effect profile and drug efficacy of thirteen adult patients who received dupilumab treatment and to evaluate the drug use status and the results during the COVID\u201019 pandemicAdult atopic dermatitis (AD), especially adult\u2010onset type appears to have different clinical manifestations. Dupilumab is an IL\u20104 receptor antagonist used in patients with moderate and severe atopic dermatitis, aged 12\u00a0years and older and it works by inhibiting the IL\u20104 and IL\u201013\u00a0signaling pathway. The purpose of dy is to retrospectively investigate the side effect profile and drug efficacy of thirteen adult patients who received dupilumab treatment and to evaluate the drug use status and the results during the COVID\u201019 pandemicAdult atopic dermatitis (AD), especially adult\u2010onset type appears to have different clinical manifestations. Dupilumab is an IL\u20104 receptor antagonist used in patients with moderate and severe atopic dermatitis, aged 12\u00a0years and older and it works by inhibiting the IL\u20104 and IL\u201013\u00a0signaling pathway. The purpose of our study is to retrospectively investigate the side effect profile and drug efficacy of thirteen adult patients who received dupilumab treatment and to evaluate the drug use status and the results during the COVID\u201019 pandemic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Thirteen patients with clinical and\/or histopathological diagnoses of atopic dermatitis who received dupilumab treatment and were subsequently followed up in Bezmialem Vakif University dermatology outpatient clinic between April 2019 and October 2021 were included in our study.Patient files were reviewed, and patients were interviewed in\u2010person or by phone to learn about the COVID\u201019 contagion.Descriptive statistical analysis was performed with Microsoft Excel, and the data obtained were calculated as mean and percentage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All of our patients responded to the treatment after one course of dupilumab injection and also CRP and LDH levels decreased. Conjunctivitis side effect was found at a slightly higher rate than in previous clinical studies. The treatment was continued during the COVID\u201019 pandemic in most patients. Meanwhile, four patients had COVID\u201019 infection, but one of them was not using dupixent at that time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We can conclude that dupilumab is an effective and safe therapy for patients with severe AD also in cases of severe infections.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.14785","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T19:54:27Z","timestamp":1642449267000},"page":"4781-4787","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single\u2010center real\u2010life experience"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-9261","authenticated-orcid":false,"given":"\u00d6zlem","family":"Su K\u00fc\u00e7\u00fck","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Faculty of Medicine Bezmialem Vakif University  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-0646","authenticated-orcid":false,"given":"Beg\u00fcm","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Faculty of Medicine Bezmialem Vakif University  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-2505","authenticated-orcid":false,"given":"Nazan","family":"Ta\u015flidere","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Faculty of Medicine Bezmialem Vakif University  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-1314","authenticated-orcid":false,"given":"Bengisu\u00a0G\u00fc\u00e7kan","family":"I\u015fik","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Faculty of Medicine Bezmialem Vakif University  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-5783","authenticated-orcid":false,"given":"Tahsin \u00c7a\u011fda\u015f","family":"Akaslan","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Faculty of Medicine Bezmialem Vakif University  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0669-6232","authenticated-orcid":false,"given":"Fatma Pelin","family":"\u00d6zgen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Faculty of Medicine Bezmialem Vakif University  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8124-1230","authenticated-orcid":false,"given":"An\u0131l G\u00fclsel","family":"Bahali","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Faculty of Medicine Bezmialem Vakif University  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"issue":"6","key":"e_1_2_9_2_1","first-page":"1","article-title":"Dupilumab for Moderate\u2010to\u2010Severe Atopic Dermatitis","volume":"22","author":"Vangipuram R","year":"2017","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3368"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16527"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.09.029"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00453-7"},{"key":"e_1_2_9_8_1","first-page":"6","article-title":"A systematic review and meta\u2010analysis of the prevalence and phenotype of adult\u2010onset atopic dermatitis","volume":"5","author":"Lee HH","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.8.1360"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18163"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18179"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000198"},{"issue":"2","key":"e_1_2_9_13_1","first-page":"190","article-title":"Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.Int","volume":"60","author":"Yamauchi T","year":"2021","journal-title":"J Dermatol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1449642"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.053"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16090"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16411"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.031"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-020-0095-7"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.015"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25685"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"e_1_2_9_26_1","unstructured":"Dupilumab Summary of Product Characteristics (SmPC) European Product Label;2017.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/dupixent\u2010epar\u2010product\u2010information_enpdf"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-020-00781-5"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3617"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13502"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.14785","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.14785","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.14785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:44:20Z","timestamp":1748353460000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.14785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/jocd.14785"],"URL":"https:\/\/doi.org\/10.1111\/jocd.14785","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"subject":[],"published":{"date-parts":[[2022,1,30]]},"assertion":[{"value":"2021-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}